EPHA2 and medulloblastoma: Interestingly, repeating i.c.v. administrations of EPHA2 CAR-T cells in medulloblastoma PDX models enhanced the overall survival in comparison to a single EPHA2 CAR-T cell treatment with no signs of severe systemic toxicities [42].